Thyroid cancer that has metastasized is almost impossible to treat. If fact, I don’t believe that conventional oncology has any real therapies for it. Stable disease lasting for a bit less than three years may not look like much but keep in mind that this therapy comes with no NCI grade 2,3 or 4 side effects.
The challenge for the cancer patient is to find a practitioner of this admittedly very alternative cancer therapy.
I am both a cancer survivor and cancer coach. While my cancer is completely different from thyroid cancer both cancers share the fact that conventional oncology considers them to be “incurable.”
I work with cancer patients to identify all possible treatment options for all types of cancer at any stage.
Scroll down the page to ask a question or make a comment.
“Purpose-Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer.
Patients and methods
We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options.
We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57–92%) were specific for a single tumor type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4 toxicities.
Thirteen patients were evaluable for response:
Conclusion-Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer.